Top

mobilizing

the wisdom to heal

The expertise to transform the way challenging diseases and conditions are treated

Noveome is a clinical-stage biopharmaceutical company advancing ST266— a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing.

ST266 contains physiologic levels of hundreds of active biomolecules, including growth factors and cytokines. These molecules modulate a host of biological pathways, including anti-inflammatory and neuroprotective mechanisms, critical to healing. Learn more about the science behind ST266 >

In both preclinical and clinical studies, ST266 has been shown to be well-tolerated with demonstrated biologic activity. We believe it holds significant promise to improve clinical outcomes in a range of complex diseases and conditions in categories as diverse as ophthalmology, neurology, dermatology and more. Explore our advancing pipeline >

leadership

Our experienced management team has an established track record of advancing promising drug candidates from discovery through development and commercialization.

William J. Golden, CFA

Founder, Chairman and CEO

BIO

Randall R. Rupp, Ph.D.

Executive Vice President of Manufacturing and Development

BIO

David L. Steed, MD

Executive VP of Medical Affairs, Chief Medical Officer

BIO

Larry R. Brown, Sc.D.

Research & Development Executive Vice President/Chief Scientific Officer

BIO

Tammy McCracken, MS

Senior Vice President, Quality & Regulatory Affairs

BIO

Kevin E. McCracken

Senior Vice President of Operations

BIO

Maria Weber, CPA

Vice President of Administration & Controller

BIO

board of directors

We are advised by an independent Board of Directors that includes experts in healthcare technology, intellectual property, investment and management.

Terence C. Golden

Board Member

BIO

William J. Golden, CFA

Founder, Chairman and CEO

BIO

Robert S. Langer, Sc.D.

Board Member

BIO

Donald J. Wagner, SR.

Board Member

BIO

Patrick T. Welch

Board Member

BIO

contact us

Noveome received seed funding and access to world-class researchers, physicians and experts in private and public reimbursement at Pittsburgh ‘s leading healthcare institutions, including UPMC Health System, Highmark Blue Cross/Blue Shield, the University of Pittsburgh and Carnegie Mellon University. We are passionate about helping the Pittsburgh region grow into the world’s next great nexus for biotechnology.

Corporate Headquarters
100 Technology Drive, Suite 200
Pittsburgh, PA 15219

Telephone
Call us at: +1.412.402.9914

General inquiries
Please contact us at:
info@noveome.com

Clinical inquiries
Please contact us at:
clinical@noveome.com

Patients
For urgent clinical inquiries,
please contact your treating physician
or clinical study investigator.

Healthcare Professionals
Please contact us at:
clinical@noveome.com

Investors Inquiries
Please contact:
Julie Seidel
Stern Investor Relations
Phone: (212) 698-8684
Email: julie.seidel@sternir.com